Replimune to resubmit melanoma drug after FDA’s Makary leaves
Thomas Fuller | Lightrocket | Getty Images Replimune plans to resubmit its melanoma drug to the Food and Drug Administration for review after a leadership exodus at the agency, the company said Friday. The FDA twice rejected Replimune’s melanoma treatment under the previous FDA leadership, including former Commissioner Marty Makary, who stepped down earlier this…